Editorial
3
Physicians, the medical device industry and the data; a healthy relationship?
EuroInterv.2006;2:19-22
4
Drug-eluting stent implantation in acute myocardial infarction. Do we need another randomised trial? (TYPHOON, PASSION and HORIZONS trials)
EuroInterv.2006;2:23-27
Working Group 10 column
6
Curriculum and syllabus for Interventional Cardiology subspecialty training in Europe
EuroInterv.2006;2:31-36
20 years of stenting
7
Pioneer clinical experiences: from bare metal Palmaz-Schatz™ to Sirolimus-Eluting CYPHER™ stents
EuroInterv.2006;2:37-39
Clinical research
9
Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial
Morice M-C, Bestehorn H-P, Carrié D, Macaya C, Aengevaeren W, Wijns W, Dubois C, de Winter R, Verheye S, Hoffmann S, Pachinger O, Di Mario C
EuroInterv.2006;2:45-52
10
Revascularization strategies of coronary multiple vessel disease in the Drug Eluting Stent Era: one year follow-up results of the ERACI III Trial
Rodriguez A, O Maree A, Grinfeld L, Fernandez-Pereira C, Mieres J, Alemparte MR, Berrocal D, Rodriguez-Granillo GA, Vigo C, Felsen M, O'Neill W, Palacios I
EuroInterv.2006;2:53-60
11
Integrated analysis of medically treated diabetic patients in the TAXUS™ program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments
EuroInterv.2006;2:61-68
12
One-year results of coronary revascularization in diabetic patients with multivessel coronary artery disease. Sirolimus stent vs. coronary artery bypass surgery and bare metal stent: insights from ARTS-II and ARTS-I
Macaya C, García-García H, Colombo A, Morice M-C, Legrand V, Kuck K-H, Sheiban I, Suttorp M, Carrié D, Vrolix M, Wittebols K, Stoll H-P, Donohoe D, Bressers M, Serruys PW
EuroInterv.2006;2:69-76
13
First-In-Man application of a miniature self-contained intracoronary magnetic resonance probe.A multi-centre safety and feasibility trial
Regar E, Hennen B, Grube E, Halon D, Wilensky RL, Virmani R, Schneiderman J, Sax S, Friedmann H, Serruys PW, Wijns W
EuroInterv.2006;2:77-83
14
First experience with the Impella Recover® LP 2.5 micro axial pump in patients with cardiogenic shock or undergoing high-risk revascularisation
EuroInterv.2006;2:84-90
15
Use of Impella Recover® LP 2.5 left ventricular assist device during high-risk percutaneous coronary interventions; clinical, haemodynamic and biochemical findings
Valgimigli M, Steendijk P, Serruys PW, Vranckx P, Boomsma F, Onderwater E, Vaina S, Ligthart J, McFadden E, van der Ent M, de Jaegere P, Sianos G
EuroInterv.2006;2:91-100
New device
16
Development and construct validation of performance metrics for multivessel coronary interventions on the VIST virtual reality simulator at PCR2005 EuroInterv.2006;2:101-106
Technical report
20
AngioJet® Rheolytic™ Thrombectomy System and innovation for Power Pulse™ Infusion
EuroInterv.2006;2:120-124
21
Left ventricular apex occluder. Description of a Ventricular Partitioning Device
EuroInterv.2006;2:125-127
Special report
22
Percutaneous ventricular restoration in a chronic heart failure patient EuroInterv.2006;2:128-131
Expert review
23
IVUS beyond the horizon
van der Steen A, Baldewsing R, Degertekin FL, Emelianov S, Frijlink M, Furukawa Y, Goertz D, Karaman M, Khuri-Yakub P, Kim K, Mastik F, Moriya T, Oralkan O, Saijo Y, Schaar J, Serruys PW, Sethuraman S, Tanaka A, Vos HJ, Witte R, O'Donnell M
EuroInterv.2006;2:132-142
Issue 5 has been released thanks to the support of the following partners:
- Cordis, a Johnson & Johnson company
- Boston Scientific
- Medtronic
- Abbott Vascular Devices
- Terumo
- Hexacath
- GE Healthcare
- Mentice
- Pie Medical Imaging
- Orbus Neich



